Atherogenic metabolic profile in PCOS patients: Role of obesity and hyperandrogenism

Gynecological Endocrinology

Volumn 26, Issue 10, 2010, Pages 736-742

  Castelo Branco, Camil ^a   Steinvarcel, Florencia ^a   Osorio, Alois ^a   Ros, Cristina ^a   Balasch, Juan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

BMI (body mass index); dyslipidemia; hyperandrogenism; PCOS (polycystic ovary syndrome); Rotterdam criteria phenotypes

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FOLLITROPIN; HYDROXYPROGESTERONE; INHIBIN A; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANOVULATION; ATHEROSCLEROSIS; BODY MASS INDEX; CARBOHYDRATE METABOLISM; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERANDROGENISM; LIPID METABOLISM; METABOLOME; OBESITY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE; YOUNG ADULT;

EID: 77956553268     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.481025     Document Type: Article

References (28)

1. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:453-462.
2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438.
3. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000;52:595-600.
4. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognised cardiovascular risk factor in women. Rev Cardiovasc Med 2009;10:83-90.
5. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
6. Rotterdam ESHRE/ASRM Sponsored Consensus Workshop Group 2004. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Ferti Steril 2004;81:19-25.
7. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781-785.
8. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006;91:786-789.
9. Rachoń D, Teede H. Ovarian function and obesity-Interrelationship, impact on women's reproductive lifespan and treatment options. Mol Cell Endocrinol, 2010 Mar 25; 316(2):172-179
10. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. Geneva, World Health Organization, 2000 (WHO Technical Report Series, No. 894; http://libdoc.who.int/trs/WHO-TRS-894.pdf, accessed November 7, 2009).
11. Balasch J, Fábregues F, Peñ arrubia J, Carmona F, Casamitja-na R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod 2006; 21(7):1884-1893.
12. Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoas-says. Eur J Endocrinol 2005;152(3):471-478.
13. Moreno-Arias G, Castelo-Branco C, Ferrando J. Paradoxical effect after IPL photoepilation. Dermatol Surg 2002;28:1013-1016.
14. Vidal J, Morinigo R, Codoceo VH, Casamitjana R, Pellitero S, Gomis R. The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjects. Int J Obes 2005;29:668-674.
15. Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008;198:670 e1-670 e10.
16. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome, Am J Med 2001;111:607-613.
17. Valkenburg O, Steegers-Theunissen RPM, Smedts HPM, Dallinga-Thie GM, Fauser BCJM, Westerveld EH, Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93:470-476.
18. Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, Ghazzi MN. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003; 88:5137-5144.
19. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992;37: 119-125.
20. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
21. Westerveld HE, Hoogendoorn M, de Jong AWF, Goverde AJ, Fauser BCJM, Dallinga-Thie GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutics insights. Pharmacol Ther 2008;119:223-241.
22. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004;89:61-70.
23. Economou F, Xyrafis X, Livadas S, Androulakis II, Argyr-akopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009;8(3):199-206.
24. Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989;68:1027-1032.
25. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositol-glycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001-2005.
26. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83-89.
27. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fert Steril 2009; 92:626-634.
28. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009;24(9):2286- 2292.